Search Results

There are 21254 results for: content related to: Exploiting Apoptosis Pathways for Glioblastoma Therapy

  1. The TRAIL Receptor-Ligand System: Biochemistry of Apoptosis Induction, Therapeutic Potential for Cancer Treatment and Physiological Function

    Apoptosis and Cancer Therapy: From Cutting-edge Science to Novel Therapeutic Concepts

    Henning Walczak, Ronald Koschny, Daniela Willen, Manuela B. Schader, Jaromir Sykora, Tom M. Ganten, Tobias L. Haas, Pages: 31–92, 2008

    Published Online : 26 MAY 2008, DOI: 10.1002/9783527619665.ch2

  2. The role of CD95/CD95 Ligand Signaling in Apoptosis and Cancer

    Apoptosis and Cancer Therapy: From Cutting-edge Science to Novel Therapeutic Concepts

    Karsten Gülow, Marcin Kamiński, Peter H. Krammer, Pages: 3–30, 2008

    Published Online : 26 MAY 2008, DOI: 10.1002/9783527619665.ch1

  3. Bag-1 and Bcl-2 Gene Transfer in Malignant Glioma: Modulation of Cell Cycle Regulation and Apoptosis

    Brain Pathology

    Volume 10, Issue 2, April 2000, Pages: 223–234, Wilfried Roth, Cornelia Grimmel, Lorenz Rieger, Herwig Strik, Shinichi Takayama, Stanislaw Krajewski, Richard Meyermann, Johannes Dichgans, John C. Reed and Michael Weller

    Version of Record online : 5 APR 2006, DOI: 10.1111/j.1750-3639.2000.tb00256.x

  4. You have free access to this content
    Differential down-regulation of CD95 or CD95L in chronically HIV-infected cells of monocytic or lymphocytic origin: cellular studies and molecular analysis by quantitative competitive RT-PCR

    FEBS Letters

    Volume 458, Issue 2, September 17, 1999, Pages: 209–214, Marcello Pinti, Jessica Pedrazzi, Francesca Benatti, Veronica Sorrentino, Cira Nuzzo, Valeria Cavazzuti, Priscilla Biswas, Daniela Nicoleta Petrusca, Cristina Mussini, Bruno De Rienzo and Andrea Cossarizza

    Version of Record online : 10 SEP 1999, DOI: 10.1016/S0014-5793(99)01131-X

  5. CD95-mediated Apoptosis of Human Glioma Cells: Modulation by Epidermal Growth Factor Receptor Activity

    Brain Pathology

    Volume 12, Issue 1, January 2002, Pages: 12–20, Joachim P. Steinbach, Petra Supra, H.-J. Su Huang, Webster K. Cavenee and Michael Weller

    Version of Record online : 5 APR 2006, DOI: 10.1111/j.1750-3639.2002.tb00418.x

  6. You have free access to this content
    T cell activation-induced and HIV Tat-enhanced CD95(APO-1 / Fas) ligand transcription involves NF-κB

    European Journal of Immunology

    Volume 30, Issue 2, February 2000, Pages: 661–670, Min Li-Weber, Oskar Laur, Kirsten Dern and Peter H. Krammer

    Version of Record online : 28 AUG 2000, DOI: 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.0.CO;2-L

  7. You have free access to this content
    Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells

    European Journal of Immunology

    Volume 31, Issue 7, July 2001, Pages: 2217–2226, Holger J. Dulat, Claudia von Grumbkow, Wiebke Baars, Natalia Schröder, Kurt Wonigeit and Reinhard Schwinzer

    Version of Record online : 4 JUL 2001, DOI: 10.1002/1521-4141(200107)31:7<2217::AID-IMMU2217>3.0.CO;2-E

  8. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker

    British Journal of Dermatology

    Volume 139, Issue 2, August 1998, Pages: 198–206, Maeda, Aragane and Tezuka

    Version of Record online : 4 JAN 2002, DOI: 10.1046/j.1365-2133.1998.02355.x

  9. You have free access to this content
    Hepatocytes as cytotoxic effector cells can induce cell death by CD95 ligand-mediated pathway

    Hepatology

    Volume 43, Issue 6, June 2006, Pages: 1231–1240, Clifford S. Guy, Jinguo Wang and Tomasz I. Michalak

    Version of Record online : 25 MAY 2006, DOI: 10.1002/hep.21201

  10. You have free access to this content
    CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo

    International Journal of Cancer

    Volume 113, Issue 1, 1 January 2005, Pages: 78–87, Frederik H. Igney, Christian K. Behrens and Peter H. Krammer

    Version of Record online : 25 AUG 2004, DOI: 10.1002/ijc.20538

  11. Cell death in the colonic epithelium during inflammatory bowel diseases: CD95/Fas and beyond

    Inflammatory Bowel Diseases

    Volume 16, Issue 6, June 2010, Pages: 1071–1076, Lina Chen, Sun-Mi Park, Jerrold R. Turner and Marcus E. Peter

    Version of Record online : 4 JAN 2010, DOI: 10.1002/ibd.21191

  12. You have free access to this content
    Diva/Boo is a negative regulator of cell death in human glioma cells

    FEBS Letters

    Volume 505, Issue 1, September 07, 2001, Pages: 23–26, Ulrike Naumann, Simone Weit, Jörg Wischhusen and Michael Weller

    Version of Record online : 17 AUG 2001, DOI: 10.1016/S0014-5793(01)02768-5

  13. You have free access to this content
    Oxidative stress and hypoxia/reoxygenation trigger CD95 (APO-1/Fas) ligand expression in microglial cells

    FEBS Letters

    Volume 429, Issue 1, June 05, 1998, Pages: 67–72, Markus Vogt, Manuel K.A Bauer, Davide Ferrari and Klaus Schulze-Osthoff

    Version of Record online : 25 JUN 1998, DOI: 10.1016/S0014-5793(98)00562-6

  14. You have free access to this content
    The influence of CD95L expression on tumor rejection in mice

    European Journal of Immunology

    Volume 33, Issue 10, October 2003, Pages: 2811–2821, Frederik H. Igney, Christian K. Behrens and Peter H. Krammer

    Version of Record online : 16 SEP 2003, DOI: 10.1002/eji.200324176

  15. You have free access to this content
    APO2 ligand: a novel lethal weapon against malignant glioma?

    FEBS Letters

    Volume 427, Issue 1, May 01, 1998, Pages: 124–128, Johannes Rieger, Ulrike Naumann, Tamara Glaser, Avi Ashkenazi and Michael Weller

    Version of Record online : 16 FEB 1999, DOI: 10.1016/S0014-5793(98)00409-8

  16. You have free access to this content
    Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells

    Hepatology

    Volume 27, Issue 1, January 1998, Pages: 200–208, Markus Müschen, Ulrich Warskulat, Patrice Douillard, Emmanuelle Gilbert and Dieter Häussinger

    Version of Record online : 30 DEC 2003, DOI: 10.1002/hep.510270131

  17. You have full text access to this Open Access content
    Death receptors as targets for anti-cancer therapy

    Journal of Cellular and Molecular Medicine

    Volume 12, Issue 6b, December 2008, Pages: 2566–2585, Kerstin Papenfuss, Stefanie M. Cordier and Henning Walczak

    Version of Record online : 6 OCT 2008, DOI: 10.1111/j.1582-4934.2008.00514.x

  18. You have free access to this content
    Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178) 1

    FEBS Letters

    Volume 519, Issue 1-3, May 22, 2002, Pages: 50–58, Markus Philipp Ghadimi, Ralf Sanzenbacher, Bernd Thiede, Jennifer Wenzel, Qian Jing, Markus Plomann, Arndt Borkhardt, Dieter Kabelitz and Ottmar Janssen

    Version of Record online : 23 APR 2002, DOI: 10.1016/S0014-5793(02)02709-6

  19. CD95 Ligand: Lethal Weapon Against Malignant Glioma?

    Brain Pathology

    Volume 8, Issue 2, April 1998, Pages: 285–293, Michael Weller, Paul Kleihues, Johannes Dichgans and Hiroko Ohgaki

    Version of Record online : 5 APR 2006, DOI: 10.1111/j.1750-3639.1998.tb00154.x

  20. CD95 ligand expression in dedifferentiated breast cancer

    The Journal of Pathology

    Volume 189, Issue 3, November 1999, Pages: 378–386, Markus Müschen, Cordula Moers, Ulrich Warskulat, Dieter Niederacher, Beate Betz, Jos Even, Annick Lim, Régis Josien, Matthias W. Beckmann and Dieter Häussinger

    Version of Record online : 27 OCT 1999, DOI: 10.1002/(SICI)1096-9896(199911)189:3<378::AID-PATH439>3.0.CO;2-D